Clene Reports Promising NfL Biomarker Data for ALS Hopeful

Clene has announced positive results from the HEALEY ALS Platform Trial, revealing that CNM-Au8 led to significant reductions in plasma neurofilament light chain concentrations in patients with amyotrophic lateral sclerosis (ALS). The company is considering filing a New Drug Application and preparing the complete CNM-Au8 clinical data package for regulatory discussions with the FDA. Developed us..